The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
T-Lymphocyte and Plasma Angiotensin-Converting Enzyme Activity During Enalapril and Losartan Administration in Humans
This study evaluated the long-term effects of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II type 1 receptor antagonist losartan on the angiotensin-converting enzyme activity in T lymphocytes and plasma in patients with essential hypertension . The study was a r and omized , placebo-controlled , double-blind , crossover design . Nine patients with sitting blood pressure ≥ 95 mm Hg and ≤ 105 mm Hg at the end of a 4-week placebo run-in period entered the double-blind phase of the study , which consisted of three 6-week periods during which patients were treated with placebo , enalapril ( 20 mg , once daily ) , or losartan ( 50 mg , once daily ) The angiotensin-converting enzyme activity in T lymphocytes was measured as the activity of the degradation of the substrate Hippuryl-His-Leu and as the appearance of the dipeptide His-Leu , which was quantified spectrofluorometrically . Enalapril but not losartan suppressed ( p ≤ 0.01 ) the angiotensin-converting enzyme activity in plasma , whereas it stimulated ( p ≤ 0.05 ) the angiotensin-converting enzyme activity in circulating T lymphocytes . Our data document induction of angiotensin-converting enzyme in human T lymphocytes during long-term treatment with the angiotensin-converting enzyme inhibitor enalapril . Angiotensin II receptor type 1 antagonism with losartan had no effect on plasma or lymphocytic angiotensin-converting enzyme
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .